On March 23, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for kidney cancer.
The version 3.2021 update features modifications to first-line and subsequent therapy for relapsed or stage IV disease and clear cell histology.
In the section labeled principles of systemic therapy for relapse or stage IV disease, under preferred regimens for first-line therapy for clear cell histology, lenvatinib + pembrolizumab was added as a category 1 recommendation for favorable risk and poor/intermediate risk disease.
In addition, under other recommended regimens for subsequent therapy for clear cell histology, tivozanib was added as a category 2A recommendation.—Janelle Bradley
